ReShape Lifesciences shareholders approve key proposals

ReShape Lifesciences Inc. (NASDAQ:RSLS), a pharmaceutical company, announced the outcomes of several critical votes taken at its special meeting on April 1, 2025. The voting results, disclosed in an SEC filing on April 2, 2025, indicate shareholder approval on all proposed items, including a reverse stock split, warrant exercisability, and an Equity Line of Credit (ELOC) agreement. According to InvestingPro data, the company’s stock has shown remarkable volatility, with a 236% return over the past week, though it remains 71% lower over the past six months.

The first proposal, which passed with 2,267,177 votes in favor, grants the company’s Board of Directors the authority to implement a reverse stock split of common stock at a ratio between 1-for-2 and 1-for-250 within one year from the meeting date. The exact ratio and timing will be determined by the Board and subsequently announced to the public. InvestingPro analysis reveals the company maintains a positive cash position relative to debt, though it’s currently experiencing rapid cash burn - just two of the 14+ insights available to subscribers.

The second proposal, receiving 106,509 affirmative votes, pertains to the exercisability of 2,703,862 common stock purchase warrants. These warrants were issued in association with a securities offering on February 18, 2025, to certain institutional investors and the company’s placement agent. The approval aligns with Nasdaq Listing Rule 5635(d) and permits the issuance of up to 15,132,975 shares of common stock underlying the warrants, which may be exercised without an exercise price.

Additionally, the third proposal, which garnered 1,444,858 votes for approval, allows for the issuance of common stock under the ELOC Purchase Agreement dated December 19, 2024. The agreement with an institutional investor permits ReShape Lifesciences to sell up to $5 million in shares over a 36-month term, subject to the terms and conditions outlined in the agreement.

These approvals by the company’s stockholders are expected to provide ReShape Lifesciences with the flexibility to manage its capital structure and funding strategy effectively. With a current market capitalization of $5.26 million and a gross profit margin of 68.19%, the company faces significant challenges, as indicated by its negative EBITDA of -$7.9 million in the last twelve months. The company, formerly known as Obalon Therapeutics (NASDAQ:OBLN_old) Inc., specializes in pharmaceutical preparations and operates under the organization name 03 Life Sciences, based in Irvine, California. For detailed analysis and comprehensive insights, investors can access the full Pro Research Report available on InvestingPro.

This news article is based on a press release statement and should be considered as information obtained from the company’s SEC filing.

In other recent news, ReShape Lifesciences has been granted an international patent by the State of Israel Patent Office for its Diabetes Neuromodulation technology, which is designed to improve glycemic control for Type 2 diabetes patients. This patent extends protection until December 2039 and is part of ReShape’s extensive intellectual property portfolio, which includes 62 issued or pending patents. Additionally, ReShape Lifesciences has amended the terms of its senior secured convertible note with Ascent Partners Fund LLC, extending the note’s maturity and adjusting prepayment conditions. This amendment is strategically aligned with ReShape’s anticipated merger with Vyome Therapeutics, Inc., providing financial flexibility ahead of the merger.

The merger between ReShape Lifesciences and Vyome Therapeutics is progressing as planned in an all-stock transaction, with ReShape set to become Vyome Holdings, Inc. and expected to trade on Nasdaq under the ticker "HIND." As part of this strategic move, ReShape has also entered into an asset purchase agreement with Biorad Medisys, which will acquire the Lap-Band, Obalon Gastric Balloon, and Diabetes Bloc-Stim Neuromodulation systems. The merger will result in a new management structure led by Vyome’s executive officers and aims to leverage U.S.-India synergies to develop therapies for chronic immune-inflammatory conditions. Paul F. Hickey, President and CEO of ReShape, has expressed confidence in the merger’s potential to create significant shareholder value.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.